GTN is an industry leader in using deep learning AI techniques in shape-based chemistry to search for new drugs. The company now reckons that its efforts in finding new drugs to fight neurodegeneration will be vastly improved by its partnership with C4X Discovery, which has expertise in dynamic 3D modelling of drug molecules.
Anna Smith writes about the GTN-C4XD alliance in PharmaTimes:
C4XD, using its conformational analysis platform Conformetrix – a technology platform that allows the dynamic 3D-shapes of free drug molecules to be precisely measured – will provide GTN with world-leading molecular descriptors for use in its in-silico discovery platform.
By combining both technologies, the collaboration will aim to unlock new areas of chemical space and identify novel small molecules, the firms said.
“This partnership is a great milestone for GTN as we expand the capabilities of our proprietary quantum machine learning platform,” noted Noor Shaker, the firm’s chief executive. “GTN will deploy its platform to discover novel, high quality chemicals and accelerate the discovery process”. She continued: “GTN’s unique approach to quantum representation of molecules and advance machine learning plays very nicely with C4XD’s molecular descriptors.”
